239 related articles for article (PubMed ID: 21317881)
1. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.
Ozcan A; Shen SS; Hamilton C; Anjana K; Coffey D; Krishnan B; Truong LD
Mod Pathol; 2011 Jun; 24(6):751-64. PubMed ID: 21317881
[TBL] [Abstract][Full Text] [Related]
2. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study.
Zhai QJ; Ozcan A; Hamilton C; Shen SS; Coffey D; Krishnan B; Truong LD
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):323-32. PubMed ID: 20216401
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.
Nonaka D; Tang Y; Chiriboga L; Rivera M; Ghossein R
Mod Pathol; 2008 Feb; 21(2):192-200. PubMed ID: 18084247
[TBL] [Abstract][Full Text] [Related]
4. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
6. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of putative renal cell carcinoma markers PAX-2, PAX-8, and hKIM-1 in germ cell tumors: a tissue microarray study of 100 cases.
Sangoi AR; McKenney JK; Brooks JD; Bonventre JV; Higgins JP
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):451-3. PubMed ID: 22495365
[TBL] [Abstract][Full Text] [Related]
8. Value of PAX 8 immunostaining in tumor diagnosis: a review and update.
Ordóñez NG
Adv Anat Pathol; 2012 May; 19(3):140-51. PubMed ID: 22498579
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin.
Mentrikoski MJ; Wendroth SM; Wick MR
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):635-41. PubMed ID: 25279712
[TBL] [Abstract][Full Text] [Related]
10. Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases.
Sangoi AR; Karamchandani J; Lane B; Higgins JP; Rouse RV; Brooks JD; McKenney JK
Mod Pathol; 2011 Mar; 24(3):425-9. PubMed ID: 21102418
[TBL] [Abstract][Full Text] [Related]
11. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
12. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
13. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
14. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
15. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
Sharma SG; Gokden M; McKenney JK; Phan DC; Cox RM; Kelly T; Gokden N
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):494-8. PubMed ID: 21102195
[TBL] [Abstract][Full Text] [Related]
16. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
17. PAX-8 expression in primary and metastatic Merkel cell carcinoma: an immunohistochemical analysis.
Sangoi AR; Cassarino DS
Am J Dermatopathol; 2013 Jun; 35(4):448-51. PubMed ID: 23612030
[TBL] [Abstract][Full Text] [Related]
18. PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?
Barr ML; Jilaveanu LB; Camp RL; Adeniran AJ; Kluger HM; Shuch B
J Clin Pathol; 2015 Jan; 68(1):12-7. PubMed ID: 25315900
[TBL] [Abstract][Full Text] [Related]
19. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study.
Tong GX; Yu WM; Beaubier NT; Weeden EM; Hamele-Bena D; Mansukhani MM; O'Toole KM
Mod Pathol; 2009 Sep; 22(9):1218-27. PubMed ID: 19525927
[TBL] [Abstract][Full Text] [Related]
20. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
